Celltrion Healthcare, Stock Price +3.73% at This Hour... 389,145 Shares Net Sold by Individuals in the Last 5 Days

As of 12:31 PM on the 25th, Celltrion Healthcare is trading at 150,000 KRW, up 3.73% from the previous day. The trading volume is 1,227,912 shares, which is 87.05% of the previous day's volume. Celltrion Healthcare is known as the exclusive distributor of Celltrion's biosimilars.

On January 25th, Jin Heung-guk, a researcher at Korea Investment & Securities, stated, "Rekkirona can achieve significant sales this year, but due to the nature of the product, it is difficult to maintain this over the long term. However, by moving away from biosimilars and developing proprietary new drugs, the visibility of long-term growth has increased, leading to a revision of the perpetual growth rate from 3.0% to 3.5%. This marks an indication that the Celltrion Group's new drug development capabilities are strengthening. The FDA sales approval application and acquisition for Rekkirona are expected to be major catalysts moving the stock price in the short term." He set the target price for Celltrion Healthcare at 160,000 KRW.

Over the past five days, individual investors have net sold 389,145 shares of Celltrion Healthcare, while foreigners and institutions have net bought 278,280 shares and 100,123 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an article auto-generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.